泽璟制药：与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议

Core Viewpoint - Zejing Pharmaceutical (688266.SH) has entered into a strategic cooperation and licensing option agreement with AbbVie for the global development and commercialization of ZG006 (Alveltamig) [1] Group 1: Agreement Details - AbbVie has obtained exclusive rights for the development and commercialization of ZG006 outside of Greater China, while Zejing retains rights within Greater China [1] - Zejing will receive an upfront payment of $100 million, along with milestone payments based on clinical progress and licensing options totaling up to $60 million [1] - If AbbVie exercises the licensing option, Zejing is eligible for up to $1.075 billion in milestone payments and will receive tiered royalties ranging from high single digits to mid-double digits on net sales of the product outside Greater China [1]